| |
/1945/iPhoneAd/1945iPhoneAd.gif [YES]
|
|
|
|
|
|
Table of Contents
|
| |
| |
|
|
CME INFORMATION
|
ACTIVITY GOAL |
| The goal of this CME/CE activity is to examine the pathophysiology, etiologic factors, classification, diagnostic criteria, and current and emerging strategies for treating and managing patients with multiple sclerosis. |
| |
TARGET AUDIENCE |
| This CME/CE activity is designed for neurologists, internal medicine specialists, family practice/primary care physicians, nurse specialists/nurse practitioners, physician assistants, and other health professionals who interact with and are involved in the management and treatment of patients with multiple sclerosis. |
| |
LEARNING OBJECTIVES |
- Analyze the contributions of proposed etiologies and pathogenetic processes in MS based on current data in order to appropriately counsel patients and form the basis of an understanding of potential therapeutic targets.
- Diagnose and classify MS in patients with neurologic symptoms, using clinical, radiologic, and other tools, in accordance with the modified McDonald Criteria.
- Use conventional MRI to accurately diagnose and monitor multiple sclerosis, in accordance with a standardized protocol from the Consortium of MS Centers
- Evaluate new imaging technologies to determine their potential future utility in diagnosis and monitoring of MS patients
- Formulate strategies to manage major acute relapses of multiple sclerosis (MS) that will shorten the duration of the exacerbation and minimize disruption of the patient’s life, while minimizing the risk of adverse effects.
- Choose a disease-modifying therapy for patients with MS based on mechanism of action, efficacy, safety, dosing/administration, and individual patient-related factors, in order to reduce the occurrence of relapses and minimize progression of disability.
- Initiate disease-modifying therapy in patients with clinically isolated syndrome likely to convert to MS in order to prevent or delay conversion to clinically definite MS.
- Evaluate emerging therapies for multiple sclerosis (MS) based on the most current information regarding efficacy, safety, dosing/administration, and mechanism of action to determine their potential role in future MS therapy.
|
| top1945 |
|
|
|
|
|
These independent CME/CE activities are supported by an educational grant from Teva Neuroscience.
|
|
Professor
Davee Department of Neurology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
|
|
|
|
|
Director, Multiple Sclerosis
Center
University of Pennsylvania
Philadelphia, Pennsylvania
|
|
|
|
|
Associate Professor of Neurology
and Radiology
Andy and Debbie Rachleff
Distinguished Professor
of Neurology
Director
Advanced Imaging in Multiple
Sclerosis (AIMS) Laboratory
University of California,
San Francisco
San Francisco, California
|
|
|
|
|
Associate Professor
Department of Neurology
Program in Immunology
University of California,
San Francisco
San Francisco, California
|
|
|
|
|
